Andrew K. Balo, EVP, Reg. Strategy, Clinical at DEXCOM INC (DXCM), sold 11,174 shares at $143.76 ($1.6M) on 2018-09-10, disclosed to the SEC on 2018-09-12.
Seasonal sale ($1.6M) by EVP, Reg. Strategy, Clinical — this insider has traded DXCM in September in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $143.76 | 2,407 | $346K | 21.5% |
| 2 | $143.76 | 2,407 | $346K | 21.5% |
| 3 | $143.76 | 3,180 | $457K | 28.5% |
| 4 | $143.76 | 3,180 | $457K | 28.5% |
| Total | $143.76 avg | 11,174 | $1.6M | 100% |
| Filing → |
| DXCM | SELL | 2021-07-08 | $2.4M | — | Filing → |
| DXCM | SELL | 2021-06-07 | $897K | — | Filing → |
| DXCM | SELL | 2021-03-12 | $4.0M | — | Filing → |